Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Summary

This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P. gingivalis bacterium, to potentially help to halt or slow down the progression of AD and its symptoms. A saliva test will be done to determine P. gingivalis infection. Tests for AD include standard questionnaires such as MMSE and a blood test for pTau217.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Alzheimer Disease
• Alzheimer Disease Due to P. Gingivalis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

55 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Lighthouse Pharmaceuticals, Inc.

Last updated on ClinicalTrials.gov

October 7, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites